MENU
AARD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Aardvark Therapeutics (AARD) Ownership - Who owns Aardvark Therapeutics?
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
274.85M
P/E Ratio
N/A
Total Cash
141.82M
Projected Growth
N/A
Total Debt
645K
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
6.54
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
AARD
Capitalization
275M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
142M
Total Cash/Share
6.54
Total Debt
645K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
137M
P/B Ratio
2.01
Cash Flow
N/A
Earnings
-1.69
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
0
Current Ratio
14.04
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-40.83M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-31.22
Shares Held By Institutions
124M
Shares Outstanding - Current
21.7M
Total Liabilities
10.6M
Total Volume MTD
N/A
Value
1
Gain YTD
N/A
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. AARD showed earnings on August 13, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information